🇯🇵April 9, 2026·1d agoDevices

Announcement of Termination of Co-Promotion of Rituxan®in Japan (Anti-CD20 Monoclonal Antibody)

Zenyaku Kogyo Co., Ltd. Chugai Pharmaceutical Co., Ltd. TOKYO, April 9, 2026 -- Zenyaku Kogyo Co., L...

Publisher

Chugai Pharmaceutical

Japan

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Zenyaku Kogyo Co., Ltd. Chugai Pharmaceutical Co., Ltd. TOKYO, April 9, 2026 -- Zenyaku Kogyo Co., L...

Source route

Continue on chugai-pharm.co.jp

Leave the platform to read the original full article on the publisher site.

Source: Chugai Pharmaceutical

Scope: Devices

Open original article

Related coverage

More related coverage

Chugai Pharmaceutical·19h ago

news releases en

Chugai Pharmaceutical: News Releases https://www.chugai-pharm.co.jp/english/index.html News Releases...

Emergent BioSolutions·22h ago

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Viz.ai·1d ago

Viz.ai Earns Back-to-Back No. 1 Ranking in Black Book Survey of AI Clinical Decision Support Solutions

Labcorp Drug Development·1d ago

Labcorp Declares Quarterly Dividend

Announcement of Termination of Co-Promotion of Rituxan®in Japan (Anti-CD20 Monoclonal Antibody) | PharmaRadar360